Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

A study conducted by researchers at the Center for Cell-Based Therapy (CTC) highlights key proteins and signaling pathways ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

VPS72 has been identified as a key genetic player in liver cancer, highlighting its role in altering fat metabolism.

Aggressive breast cancer can become unresponsive to monoclonal antibody treatment, but targeting tumor-resident bacteria may extend its effectiveness.

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...